Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assertio Holdings, Inc. stock logo
ASRT
Assertio
$0.81
+3.5%
$0.91
$0.73
$8.01
$77.30M0.961.03 million shs94,719 shs
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
$0.06
+0.2%
$0.05
$0.03
$11.15
$674K0.6759,889 shs899 shs
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
$9.09
$9.06
$4.01
$9.10
$1.20B0.834.50 million shsN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$0.65
+2.8%
$0.76
$0.27
$1.75
$11.26M1.194.23 million shs14,956 shs
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
$1.08
$1.06
$0.88
$3.39
$81.45M1.93365,469 shs73,638 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-9.30%+4.12%-23.03%-10.55%-84.30%
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
+1.66%-3.68%-4.75%-9.84%-99.26%
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
0.00%0.00%0.00%0.00%+84.01%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-4.49%-7.45%-14.78%+72.53%-44.96%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
+1.89%+4.85%+6.93%-11.48%-14.96%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Assertio Holdings, Inc. stock logo
ASRT
Assertio
1.0447 of 5 stars
3.50.00.00.00.01.71.3
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
2.1848 of 5 stars
3.00.00.04.83.20.00.6
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.4758 of 5 stars
3.55.00.00.00.61.70.6
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
1.1308 of 5 stars
3.54.00.00.00.60.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assertio Holdings, Inc. stock logo
ASRT
Assertio
3.00
Buy$5.50576.76% Upside
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
2.00
Hold$2.003,529.76% Upside
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
2.00
HoldN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
3.00
Buy$2.00210.08% Upside
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
3.00
Buy$4.00270.37% Upside

Current Analyst Ratings

Latest ONCY, ASRT, CTIC, BLPH, and MNPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2024
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$2.00
4/4/2024
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$3.00
2/14/2024
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assertio Holdings, Inc. stock logo
ASRT
Assertio
$152.07M0.51$0.68 per share1.19$1.46 per share0.56
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/AN/AN/AN/A$0.27 per shareN/A
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
$53M22.62N/AN/A($0.14) per share-64.93
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/A$0.38 per shareN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/A$0.27 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$331.94M-$3.97N/A4.28N/A-218.28%6.30%3.54%5/6/2024 (Confirmed)
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
-$19.83M-$0.84N/AN/AN/A-187.35%-104.97%5/13/2024 (Estimated)
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
-$92.99M-$0.58N/A26.74N/A-91.38%N/A-55.82%N/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$8.40M-$0.61N/AN/AN/AN/A-115.79%-88.05%5/9/2024 (Estimated)
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$20.56M-$0.30N/AN/AN/AN/A-105.97%-72.80%5/3/2024 (Estimated)

Latest ONCY, ASRT, CTIC, BLPH, and MNPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2024N/A
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$0.01N/A+$0.01N/AN/AN/A  
4/26/2024N/A
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/A-$0.42-$0.42N/AN/AN/A
3/28/2024Q4 2023
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.17-$0.12+$0.05-$0.12N/AN/A
3/11/2024Q4 2023
Assertio Holdings, Inc. stock logo
ASRT
Assertio
N/A$0.08+$0.08$0.77$31.42 million$32.99 million
3/7/2024Q4 2023
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$0.11-$0.04+$0.07-$0.04N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Assertio Holdings, Inc. stock logo
ASRT
Assertio
N/AN/AN/AN/AN/A
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/AN/AN/AN/AN/A
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assertio Holdings, Inc. stock logo
ASRT
Assertio
0.28
1.83
1.43
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/A
3.96
3.96
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
N/A
1.27
1.26
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/A
4.17
4.17
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/A
9.01
9.01

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Assertio Holdings, Inc. stock logo
ASRT
Assertio
48.96%
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
10.61%
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
91.45%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1.83%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
6.82%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Assertio Holdings, Inc. stock logo
ASRT
Assertio
5395.12 million87.61 millionOptionable
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
1812.23 million11.60 millionNo Data
CTI BioPharma Corp. stock logo
CTIC
CTI BioPharma
127131.88 million121.84 millionOptionable
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1117.45 million10.19 millionNot Optionable
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
2975.42 million75.35 millionNot Optionable

ONCY, ASRT, CTIC, BLPH, and MNPR Headlines

SourceHeadline
Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual MeetingOncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
finanznachrichten.de - April 25 at 9:25 AM
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual MeetingOncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
prnewswire.com - April 25 at 7:00 AM
Closing Bell: Oncolytics Bio up on Friday (ONC)Closing Bell: Oncolytics Bio up on Friday (ONC)
theglobeandmail.com - April 21 at 5:51 PM
Biotech Breakthroughs Spearhead Fight Against Rising Breast Cancer CasesBiotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Cases
theglobeandmail.com - April 13 at 12:42 AM
USA News Group: Biotech Innovations Paving the Way in Breast Cancer FightUSA News Group: Biotech Innovations Paving the Way in Breast Cancer Fight
finanznachrichten.de - April 11 at 2:15 PM
Oncolytics seeking FDA meeting to discuss registration-enabling studyOncolytics seeking FDA meeting to discuss registration-enabling study
msn.com - April 11 at 2:15 PM
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
prnewswire.com - April 11 at 7:00 AM
Oncolytics Biotech (NASDAQ:ONCY) Now Covered by Analysts at Raymond JamesOncolytics Biotech (NASDAQ:ONCY) Now Covered by Analysts at Raymond James
marketbeat.com - April 4 at 2:58 PM
USA News Group: Biotechs Role in Addressing the Pancreatic Cancer EmergencyUSA News Group: Biotech's Role in Addressing the Pancreatic Cancer Emergency
finanznachrichten.de - March 14 at 9:24 AM
Buy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment TrialsBuy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment Trials
markets.businessinsider.com - March 11 at 7:59 AM
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call TranscriptOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 10 at 10:18 AM
Buy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical TrialsBuy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical Trials
markets.businessinsider.com - March 8 at 8:46 PM
Oncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsOncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
finanznachrichten.de - March 8 at 10:45 AM
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsOncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
prnewswire.com - March 7 at 4:01 PM
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANOncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
prnewswire.com - March 5 at 7:00 AM
Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisianas 3rd Annual NeauxCancer ConferenceOncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference
prnewswire.com - February 28 at 7:00 AM
Heres Why Were Watching Oncolytics Biotechs (TSE:ONC) Cash Burn SituationHere's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
finance.yahoo.com - February 15 at 3:44 PM
Oncolytics Biotech IncOncolytics Biotech Inc
baystreet.ca - February 15 at 10:44 AM
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation TreatmentsCancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments
newsfilecorp.com - February 15 at 8:00 AM
Oncolytics Biotech Inc.: Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer CohortOncolytics Biotech Inc.: Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
finanznachrichten.de - February 14 at 1:27 PM
Oncolytics Biotech® Inc.: Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer CohortOncolytics Biotech® Inc.: Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
finanznachrichten.de - February 14 at 8:27 AM
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer CohortOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
finance.yahoo.com - February 14 at 8:27 AM
Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer CohortOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort
prnewswire.com - February 14 at 7:00 AM
Outlook stock rallies on private placement, FDA study agreementOutlook stock rallies on private placement, FDA study agreement
msn.com - January 23 at 11:32 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Assertio logo

Assertio

NASDAQ:ASRT
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Bellerophon Therapeutics logo

Bellerophon Therapeutics

NASDAQ:BLPH
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
CTI BioPharma logo

CTI BioPharma

NASDAQ:CTIC
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Monopar Therapeutics logo

Monopar Therapeutics

NASDAQ:MNPR
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Oncolytics Biotech logo

Oncolytics Biotech

NASDAQ:ONCY
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.